Value Assessment Approaches for Duchenne Muscular Dystrophy Therapies

Check out my new paper titled “Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies“. The abstract is below. Purpose: Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The…

Read More

Can appointment-based models (ABM) reduce total cost of care?

Managing multiple medications is a challenge for many individuals, particularly the elderly. One study by Almodóvar et al. (2019) found that among Medicare beneficiaries eligible for medication therapy management (MTM), 51% had used 11 or more medications. One approach to improving medication management is to use an appointment-based model (ABM) and other forms of medication…

Read More

Biology to the Rescue?

By KIM BELLARD I feel much about synthetic biology as I do AI: I don’t really understand it from a technical point of view, but I sure am excited about its potential. Sometimes they even overlap, as I’ll discuss later. But I’ll start with some recent developments with bioplastics, a topic I have somehow never…

Read More

Listen to the Latest ‘KFF Health News Minute’

Aug. 22 This week on the KFF Health News Minute: New treatments and vaccines are available for respiratory syncytial virus, or RSV, and fentanyl-laced stimulants are driving a new wave of opioid overdose deaths. Aug. 15 This week on the KFF Health News Minute: Fears about social media may cause policymakers to miss the mental…

Read More